Passer au contenu principal

Bruno Larrivée

Larrivée, Bruno

Associate professor

Affiliation

Université de Montréal

Research Axes

Vision health

Contact information

Phone: 514-252-3400, poste7749

bruno.larrivee@umontreal.ca

Team

  • Naoufal Akla
  • Victor Bisson
  • Érika Hooker
  • Cindy Lora
  • Natalija Popovic
  • Mihai Alexandru Popovici

Bruno Larrivée has a PhD in experimental medicine and heads the Developmental and Pathological Angiogenesis Research Unit. He is also an associate professor in the Department of Ophthalmology at Université de Montréal. His research focuses on factors that mediate the quiescence and integrity of blood vessels during physiological and pathological angiogenesis.

Research Unit

Developmental and Pathological Angiogenesis

Our laboratory studies developmental and pathological angiogenesis to identify new signalling pathways that control the formation and morphogenesis of blood vessels. Our research goal is to advance fundamental knowledge of blood vessel formation. The ability to control the growth of blood vessels may have important therapeutic implications for the treatment of eye diseases and solid tumours.

Induced formation of new blood vessels (angiogenesis) in the eye is frequently associated with various disorders that can lead to severe vision loss or blindness. Diabetic retinopathy and age-related macular degeneration are the leading types of these disorders in the Western world. Current therapies to delay unwanted ocular angiogenesis include laser surgery or the inhibition of vascular endothelial growth factor (VEGF), a factor with significant pro-angiogenic properties. However, identifying alternative or complementary pathways to VEGF may lead to the development of more effective and safer inhibitors of ocular angiogenesis.

Ongoing projects

1. The laboratory is looking to understand the mechanisms of BMP family signalling in endothelial cells. Our particular research aim is to develop strategies for modulating vascular signalling in eye diseases characterized by excessive blood vessel growth. Our goal is to identify and characterize new angiogenesis inhibitors that are more effective than the current VEGF inhibitors used in a clinical setting and that do not have some of the adverse effects of these inhibitors.

2. The laboratory's second research project is to develop strategies for tumour vascular normalization. We want to develop new strategies to improve blood vessel function in tumours (a process called vascular normalization) with the goal of developing new treatments to increase the therapeutic index of chemotherapy and radiation therapy.

  • Akla N, Viallard C, Popovic N, Lora Gil C, Sapieha P, Larrivée B. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability. Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1821-1836.
    More detail
  • Mazzaferri J, Larrivée B, Cakir B, Sapieha P, Costantino S. A machine learning approach for automated assessment of retinal vasculature in the oxygen induced retinopathy model. Sci Rep. 2018 Mar 2;8(1):3916.
    More detail
  • Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017 Nov;20(4):409-426.
    More detail
  • Ola R, Dubrac A, Han J, Zhang F, Fang JS, Larrivée B, Lee M, Urarte AA, Kraehling JR, Genet G, Hirschi KK, Sessa WC, Canals FV, Graupera M, Yan M, Young LH, Oh PS, Eichmann A. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun. 2016 Nov 29;7:13650.
    More detail
  • Kraehling JR, Chidlow JH, Rajagopal C, Sugiyama MG, Fowler JW, Lee MY, Zhang X, Ramírez-Hidalgo CM, Park EJ, Tao B, Chen K, Kuruvilla L, Larrivée B, Folta-Stogniew E, Ola R, Rotllan N, Zhou W, Nagle MW, Herz J, Williams KJ, Eichmann A, Lee WL, Fernández-Hernando C and Sessa WC. Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells. Sous Presse. Nat Commun. 2016 Nov 21;7:13516.
    More detail
  • Baeyens N,*, Larrivée B,*, Ola R, Huang B, Ross TD, Dubrac A, Tong H, Tsarfati M, Coon BG, Gerhold KA, Tanaka K, Hayward B, Eichmann A and Schwartz MA. Defective fluid shear stress mechanotransduction mediates hereditary hemorrhagic telangiectasia (HHT). The Journal of Cell Biology. 2016 vol. 214 no. 7. * Equal Contribution.
    More detail
  • Ntumba K, Akla N, Oh SP, Eichmann A, Larrivee B. BMP9/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration. Oncotarget. 2016 Aug 10.
    More detail
  • Li N, Hwangbo C, Jaba IM, Zhang J, Papangeli I, Han J, Mikush N, Larrivée B, Eichmann A, Chun HJ, Young LH, Tirziu D. miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Sci Rep. 2016 Feb 18;6:21228.
    More detail
  • Brunet I, Gordon E, Han J, Cristofaro B, Broqueres-You D, Liu C, Bouvrée K, Zhang J, del Toro R, Mathivet T, Larrivée B, Jagu J, Pibouin-Fragner L, Pardanaud L, Machado MJ, Kennedy TE, Zhuang Z, Simons M, Levy BI, Tessier-Lavigne M, Grenz A, Eltzschig H, Eichmann A. Netrin-1 controls sympathetic arterial innervation. J Clin Invest. 2014 Jul;124(7):3230-40.
    More detail
  • Prahst C, Kasaai B, Moraes F, Jahnsen ED, Larrivee B, Villegas D, Pardanaud L, Pibouin-Fragner L, Zhang F, Zaun HC, Eichmann A, Jones EA. The H2.0-like homeobox transcription factor modulates yolk sac vascular remodeling in mouse embryos. Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1468-76.
    More detail

Education

  • Research associate

    Yale Cardiovascular Research Center

  • Postdoctoral fellowship

    INSERM U833, Collège de France

  • PhD in experimental medicine

    University of British Columbia

Awards

  • 2016 Louise Rousselle Trottier Award  (Heart & Stroke Foundation)
  • 2014 New Investigator Award  (Heart & Stroke Foundation)
  • 2013 Scientist Development Award  (American Heart Association)